Hikma Pharmaceuticals (LON:HIK) Shares Pass Above Two Hundred Day Moving Average – Here’s What Happened

Posted by Stephan Jacobs on May 22nd, 2026

Hikma Pharmaceuticals PLC (LON:HIK – Get Free Report)’s stock price passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of GBX 1,471.09 and traded as high as GBX 1,487. Hikma Pharmaceuticals shares last traded at GBX 1,479, with a volume of 29,849,609 shares trading hands.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. Jefferies Financial Group increased their price target on Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the company a “buy” rating in a research report on Tuesday, May 5th. Berenberg Bank reiterated a “buy” rating and issued a GBX 1,800 price target on shares of Hikma Pharmaceuticals in a research report on Tuesday, April 28th. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Hikma Pharmaceuticals has an average rating of “Buy” and a consensus price target of GBX 2,128.

Check Out Our Latest Research Report on HIK

Hikma Pharmaceuticals Price Performance

The stock has a 50-day moving average of GBX 1,342.98 and a two-hundred day moving average of GBX 1,468.42. The firm has a market cap of £3.13 billion, a price-to-earnings ratio of 8.06, a price-to-earnings-growth ratio of 2.38 and a beta of 0.64. The company has a current ratio of 1.82, a quick ratio of 1.27 and a debt-to-equity ratio of 63.59.

About Hikma Pharmaceuticals

(Get Free Report)

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.